Use of Acid Suppression Medication is Associated with Risk for C. difficile Infection in Infants and Children: A Population-based Study

Clinical Infectious Diseases

Volumn 61, Issue 6, 2015, Pages 912-917

  Freedberg, Daniel E ^a   LamousCrossed D Sign Smith, Esi S ^a   Lightdale, Jenifer R ^b   Jin, Zhezhen ^c   Yang, Yu Xiao ^d   Abrams, Julian A ^a  

^a NewYork Presbyterian Hospital   (United States)

^b UMass Memorial Health Center   (United States)

^c Department of Medicine   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Clostridium difficile infection; histamine 2 receptor antagonists; microbiome; pharmacoepidemiology; proton pump inhibitors

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR;

ADOLESCENT; ARTICLE; CHILD; CHILD HOSPITALIZATION; CLOSTRIDIUM DIFFICILE INFECTION; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FOLLOW UP; HUMAN; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; CASE CONTROL STUDY; CHEMICALLY INDUCED; CLOSTRIDIUM INFECTIONS; COLITIS; ISOLATION AND PURIFICATION; PEPTOCLOSTRIDIUM DIFFICILE; PRESCHOOL CHILD; RISK ASSESSMENT;

ADOLESCENT; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COLITIS; FEMALE; HISTAMINE H2 ANTAGONISTS; HUMANS; INFANT; MALE; PROTON PUMP INHIBITORS; RISK ASSESSMENT;

EID: 84940656708     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ432     Document Type: Article

References (40)

1. Khanna S, Baddour LM, Huskins WC, et al. The epidemiology of Clostridium difficile infection in children: a population-based study. Clin Infect Dis 2013; 56:1401-6.
2. Wendt JM, Cohen JA, Mu Y, et al. Clostridium difficile infection among children across diverse US geographic locations. Pediatrics 2014; 133:651-8.
3. Chai G, Governale L, McMahon AW, Trinidad JP, Staffa J, Murphy D. Trends of outpatient prescription drug utilization in US children, 2002-2010. Pediatrics 2012; 130:23-31.
4. Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013; 108:308-28; quiz 29.
5. Barron JJ, Tan H, Spalding J, Bakst AW, Singer J. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr 2007; 45:421-7.
6. Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? Am J Gastroenterol 2003; 98:51-8.
7. Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107:1011-9.
8. Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficileassociated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012; 107:1001-10.
9. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170:784-90.
10. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294:2989-95.
11. Lewis JD, Schinnar R, Bilker WB,Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16:393-401.
12. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010; 60:e128-36.
13. Ruigomez A, Rodriguez LA, Wallander MA, Johansson S, Dent J. Endoscopic findings in a cohort of newly diagnosed gastroesophageal reflux disease patients registered in a UK primary care database. Dis Esophagus 2007; 20:504-9.
14. Ruigomez A, Johansson S,Wernersson B, Fernandez Cantero O, Garcia Rodriguez LA. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response. Scand J Gastroenterol 2012; 47:751-61.
15. Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007; 150:262-7, 267.e1.
16. Crews JD, Koo HL, Jiang ZD, Starke JR, DuPont HL. A hospital-based study of the clinical characteristics of Clostridium difficile infection in children. Pediatr Infect Dis J 2014; 33:924-8.
17. Lavelle TA, Weinstein MC, Newhouse JP, Munir K, Kuhlthau KA, Prosser LA. Economic burden of childhood autism spectrum disorders. Pediatrics 2014; 133:e520-9.
18. Booth N. What are the Read Codes? Health Libr Rev 1994; 11:177-82.
19. Lubin JH, Gail MH. Biased selection of controls for case-control analyses of cohort studies. Biometrics 1984; 40:63-75.
20. Hensgens MP, Goorhuis A, Dekkers OM, Kuijper EJ. Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics. J Antimicrob Chemother 2012; 67:742-8.
21. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000; 320:1240-3.
22. Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 1998; 17:407-29.
23. Chitnis AS, Holzbauer SM, Belflower RM, et al. Epidemiology of community-associated Clostridium difficile infection, 2009 through 2011. JAMA Intern Med 2013; 173:1359-67.
24. Targownik LE, Leslie WD, Davison KS, et al. The relationship between proton pump inhibitor use and longitudinal change in bonemineral density: a population-based study [corrected] from the CanadianMulticentre Osteoporosis Study (CaMos). Am J Gastroenterol 2012; 107:1361-9.
25. Leontiadis GI, Miller MA, Howden CW. How much do PPIs contribute to C. difficile infections? Am J Gastroenterol 2012; 107:1020-1.
26. Turco R, Martinelli M, Miele E, et al. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Aliment Pharmacol Ther 2010; 31:754-9.
27. Nylund CM, Eide M, Gorman GH. Association of Clostridium difficile infections with acid suppression medications in children. J Pediatr 2014; 165:979-84.e1.
28. Le Saux N, Gravel D, Mulvey MR, et al. Pediatric Clostridium difficile infection: 6-year active surveillance in a defined patient population. Infect Control Hosp Epidemiol 2014; 35:904-6.
29. Jangi S, Lamont JT. Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J Pediatr Gastroenterol Nutr 2010; 51:2-7.
30. Denno DM, Shaikh N, Stapp JR, et al. Diarrhea etiology in a pediatric emergency department: a case control study. Clin Infect Dis 2012; 55:897-904.
31. Sathyendran V, McAuliffe GN, Swager T, Freeman JT, Taylor SL, Roberts SA. Clostridium difficile as a cause of healthcare-associated diarrhoea among children in Auckland, New Zealand: clinical and molecular epidemiology. Eur J Clin Microbiol Infect Dis 2014; 33:1741-7.
32. Rosen R, Amirault J, Liu H, et al. Changes in gastric and lung microflora with acid suppression: acid suppression and bacterial growth. JAMA Pediatrics 2014; 168:932-7.
33. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med 2011; 365:1693-703.
34. Perez-Cobas AE, Gosalbes MJ, Friedrichs A, et al. Gut microbiota disturbance during antibiotic therapy: a multi-omic approach. Gut 2013; 62:1591-601.
35. Bajaj JS, Cox IJ, Betrapally NS, et al. Systems biology analysis of omeprazole therapy in cirrhosis demonstrates significant shifts in gut microbiota composition and function. Am J Physiol Gastrointest Liver Physiol 2014; 307:G951-7.
36. Seto CT, Jeraldo P, Orenstein R, Chia N, DiBaise JK. Prolonged use of a proton pump inhibitor reduces microbial diversity: implications for Clostridium difficile susceptibility. Microbiome 2014; 2:42.
37. Koenig JE, Spor A, Scalfone N, et al. Succession of microbial consortia in the developing infant gut microbiome. Proc Natl Acad Sci USA 2011; 108(suppl 1):4578-85.
38. Parez N, Pozzetto B, Texier N, Mory O, Garbarg-Chenon A, Tehard B. [Incidence of rotavirus gastroenteritis among children under 5 years consulting a paediatrician or a general practitioner in France]. Pathol Biol (Paris) 2013; 61:99-107.
39. Jones R, Liker HR, Ducrotte P. Relationship between symptoms, subjective well-being and medication use in gastro-oesophageal reflux disease. Int J Clin Pract 2007; 61:1301-7.
40. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol 2009; 104(suppl 2):S27-32.